AL Amyloidosis
Conditions
Sponsors
Caelum Medical Monitor
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Each patient must meet the following criteria to be enrolled in this study. 1. Provide written informed consent and be willing and able to comply with all study procedures 2. Adult, 18 years and older 3. AL amyloidosis Mayo stage IIIa based on the 2013 European Modification of the 2004 Standard Mayo Clinic Staging in patients with advanced cardiac involvement at the time of Screening 4. Measurable hematologic disease at Screening as defined by at least one of the following: a. Involved/Uninvolved Free Light Chain Difference (dFLC) > 4 mg/dL or b. Involved Free Light Chain (iFLC) > 4 mg/dL with abnormal ratio or c. Serum Protein Electrophoresis (SPEP) m-spike > 0.5 g/dL 5. Histopathological diagnosis of amyloidosis AND confirmation of AL derived amyloid deposits by at least one of the following: a. Immunohistochemistry or b. Mass spectrometry or c. Characteristic electron microscopy appearance 6. Cardiac involvement as defined by: a. Documented clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure AND b. At least one of the following: i. Endomyocardial biopsy demonstrating AL cardiac amyloidosis or ii. Echocardiogram demonstrating a mean left ventricular wall thickness > 12 mm at diastole in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening or iii. Cardiac MRI with gadolinium contrast agent diagnostic or cardiac amyloidosis 7. Planned first-line treatment for plasma cell disorder is CyBorD administered as Standard of Care (SoC) 8. Adequate bone marrow reserve and hepatic and renal function as demonstrated by: a. Absolute neutrophil count >= 1.0 x 109/L b. Platelet count >= 75 x 109/L c. Hemoglobin >= 9 g/dL d. Total direct bilirubin = 15 mL/min 9. Women of childbearing potential (WOCBP) must have a negative pregnancy test during Screening and must agree to use effective physician approved contraception from Screening to 90 days following the last study drug administration 10. Men must be surgically sterile or must agree to use effective physician approved contraception from Screening to 90 days following the last study drug administration
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will not be permitted entry to the study. 1.Have any other form of amyloidosis other than AL amyloidosis 2.Received prior therapy for AL amyloidosis or multiple myeloma. A maximum exposure of 160 mg dexamethasone (or equivalent corticosteroid) since diagnosis of AL amyloidosis and prior to randomization is allowed. 3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma or POEMS syndrome 4.Have supine systolic blood pressure 30 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion 5.Taking prednisone or its equivalent > 10 mg/day 6.Taking doxycycline 7.Receiving dialysis 8.Planned stem cell transplant during the first 6 months of protocol therapy. Stem cell collection during the protocol therapy is permitted. 9.Have had myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias within 6 months prior to screening or percutaneous cardiac intervention with recent stent or coronary artery bypass grafting within 4 months prior to screening 10.Left Ventricular Ejection Fraction (LVEF) is 550 msec. Participants who have a pacemaker may be included regardless of calculated QTc interval. 14.There is evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following: a.First degree Atrioventricular (AV)-block b.Second degree AV-block Type 1 (Mobitz Type 1/Wenckebach type) c.Right or left bundle branch block d.Atrial fibrillation with a controlled ventricular rate. (An uncontrolled ventricular rate [i.e., > 110 beats per minute] determined by an average of three beats in lead II or representative beats in lead II is not allowed) 15.Have had major surgery within 4 weeks of randomization or is planning major surgery during the study. Patients with surgical procedures conducted under local anesthesia may participate 16.There is active malignancy (including lymphoma) with the exception of any of the following: a.Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer b.Adequately treated stage I cancer from which the patient is currently in remission and has been in remission for > 2 years c.Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 mg/mL d.Other localized and/or low risk malignancies may be permitted with Medical Monitor approval. 17.Have received an investigational drug/device in another clinical investigational study within 60 days before Screening 18. Hypersensitivity to the study drug 19. Have received a live vaccine within 4 weeks prior to first dose of CyBorD 20. Women who are breast feeding 21. Have any other medical, social or psychological factors that could affect the patient's safety or ability to co
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To determine if CAEL-101 and treatment for PCD improves overall survival in Mayo stage IIIa AL amyloidosis patients who are treatment naive compared to treatment for PCD alone -To evaluate the safety and tolerability of CAEL-101 in combination with treatment for PCD | — |
Countries
Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Japan, Poland, Russia, Spain, UK, US
Contacts
Public ContactClinical Trials information Caelum
IQVIA Services Japan G.K.
Outcome results
None listed